参考文献:1.American Cancer Society: Cancer Facts and Figures 2014. Atlanta: American Cancer Society, 2014. 2.Salani R, Backes FJ, Fung K, Holschneider CH, Parker LP, Bristow RE, Goff BA. Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204:466鈥?8.CrossRef PubMed 3.Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev. 2014;2:CD009786.PubMed 4.Rettenmaier NB, Rettenmaier CR, Wojciechowski T, Abaid LN, Brown JV III, Micha JP, Goldstein BH. The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. Br J Cancer. 2010;103:1657鈥?2.PubMedCentral CrossRef PubMed 5.Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet. 2010;108:123鈥?.CrossRef PubMed 6.Frederick PJ, McQuinn L, Milam MR, et al. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:831鈥?.CrossRef PubMed 7.Petrillo M, Fagotti A, Ferrandina G, et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol. 2013;131:36鈥?1.CrossRef PubMed 8.Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685鈥?1.CrossRef PubMed 9.Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol. 2013;129:336鈥?0.CrossRef PubMed 10.Fagotti A, Petrillo M, Costantini B, et al. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series. Gynecol Oncol. 2014;132:303鈥?.CrossRef PubMed 11.Gallotta V, Fagotti A, Fanfani F, et al. Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc. 2014;28:1808鈥?5.CrossRef PubMed 12.Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144鈥?3.CrossRef PubMed 13.Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002;99:1008鈥?3.CrossRef PubMed 14.Friedman RL, Eisenkop SM, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer. 1995;76:1606鈥?4.CrossRef PubMed 15.Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, Graeff H. Radical surgical procedure improves survival time in patients with ovarian cancer. Cancer. 1992;70:2129鈥?6.CrossRef PubMed 16.Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol. 1989;34:334鈥?.CrossRef PubMed 17.Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5:26鈥?5.CrossRef PubMed 18.Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71:1397鈥?12.CrossRef PubMed 19.Petrillo M, Pedone Anchora L, Tortorella L, et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol. 2014;134:257鈥?1.CrossRef PubMed 20.Blanchard P, Plantade A, Pages C, Afchain P, Louvet C, Tournigand C, de Gramont A. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol. 2007;104:41鈥?.CrossRef PubMed 21.BenedettiPanici P, Perniola G, Angioli R, et al. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery. Int J Gynecol Cancer. 2007;17:1245鈥?1.CrossRef PubMed 22.Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007;104:686鈥?0.CrossRef PubMed 23.Uzan C, Morice P, Rey A, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol. 2004;11:658鈥?4.CrossRef PubMed 24.Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer. 2006;42:2296鈥?02.CrossRef PubMed
作者单位:A. Musella (1) C. Marchetti (1) I. Palaia (1) G. Perniola (1) M. Giorgini (1) F. Lecce (1) L. Vertechy (1) R. Iadarola (1) F. De Felice (2) M. Monti (1) L. Muzii (1) R. Angioli (3) P. Benedetti Panici (1)
1. Department of Gynecological and Obstetrical Sciences and Urological Sciences, 鈥淪apienza鈥?University of Rome, Rome, Italy 2. Department of Radiotherapy, Policlinico Umberto I, 鈥淪apienza鈥?University of Rome, Rome, Italy 3. Department of Obstetrics and Gynecology, Campus Biomedico University of Rome, Rome, Italy
刊物主题:Surgical Oncology; Oncology; Surgery;
出版者:Springer US
ISSN:1534-4681
文摘
Background The purpose of this study was to observe the role of secondary cytoreductive surgery in platinum-resistant recurrent ovarian cancer (OC) patients.